RDY - Dr. Reddy's acquires MenoLabs business from Amyris

2024-01-03 06:16:20 ET

Dr. Reddy's Laboratories ( NYSE: RDY ) on Wednesday announced a deal to acquire a women's health and dietary supplements portfolio of brands from Amyris ( OTC:AMRSQ ) as part of the latter's Chapter 11 sales process.

Terms of the deal were not disclosed.

Amyris ( OTC:AMRSQ ) filed Chapter 11 bankruptcy proceedings in August last year, with plans to sell its consumer brands to improve its liquidity position.

The acquisition by Dr. Reddy's ( RDY ) covers the MenoLabs supplements portfolio which includes seven branded products to address symptoms of perimenopause and menopause. It also includes the MenoLife health tracker app which supports the product line and provides community, education, and information to consumers regarding menopause.

"The MenoLabs acquisition will serve as a catalyst to accelerate growth in this space and build upon our aspiration to lead in the fast-growing women’s nutritional and wellness markets. The acquisition complements Dr. Reddy's U.S. self-care and wellness business portfolio of brands and addresses unmet needs of consumers for science-based, research-driven products that provide relief from the symptoms of menopause. For these and many other reasons, I believe we are well-positioned to successfully integrate and grow the business," said Marc Kikuchi, chief executive officer for Dr. Reddy's in North America.

More on Amyris, Dr. Reddy's, etc.

• Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements
• Dr Reddy's Laboratories Ltd (RDY) Q2 2024 Earnings Call Transcript
• Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook
• Dr. Reddy's acquires 6.46% stake in Israeli biotech Edity Therapeutics
• Dr. Reddy's falls as FDA flags concerns on factory site

For further details see: